Gyeonggi Business & Science Accelerator (GBSA) holds a technology transfer agreement ceremony for its patented bio technologies at the Gwanggyo Bio Center. Front row, from second left: Wan Kang, Director of Nanovique; Hyun-gon Kim, President of GBSA; Jerry Bae, CEO of 3H LABS; and Bong-Gi Lee, Professor at Pukyong National University | Photo provided by GBSA
Gyeonggi Business & Science Accelerator (GBSA) signed a “Technology Transfer Agreement for Patented Technologies Owned by GBSA” with Gyeonggi-based bio startups 3H LABS and Nanovique on Wednesday, the 22nd, at the Bio Industry Division conference room in Gwanggyo Technovalley. The agreement aims to facilitate the transfer of public research outcomes to the private sector.
This agreement was established to promote the commercialization of new drugs and functional products by transferring bio-source technologies developed by GBSA, with support from Gyeonggi-do, to private companies.
Gyeonggi-do and GBSA are actively promoting the practical application and industrial dissemination of R&D outcomes to ensure that public research results are utilized in corporate fields.
The signing ceremony was attended by GBSA President Hyun-gon Kim, 3H LABS CEO Jerry Bae, Nanovique Director Wan Kang, and around 15 other related officials.
The event included technology presentations, discussions, the signing ceremony, and commemorative photos. The companies also discussed commercialization plans and future directions for research cooperation during the session.
The technologies transferred include two items: a blood sugar–lowering composition using fermented adlay rice bran extract (to 3H LABS) and an anti-obesity composition using fucoxanthin compounds extracted from the seaweed Sargassum confusum (to Nanovique).
The blood sugar–lowering composition, jointly developed by GBSA and Pukyong National University, is effective in animal testing, with increased expression of glucose absorption genes and improved blood sugar regulation. It is expected to be used as a material for diabetes treatments and as a functional food ingredient.
The fucoxanthin component extracted from Sargassum confusum, a type of seaweed, has shown activity in inhibiting fat cell differentiation and holds strong potential for developing functional products to prevent and improve obesity.
This technology transfer marks a follow-up achievement from the “2025 Beauty & Health Material Technology Commercialization Briefing Session” hosted by GBSA in July.
At that event, over 150 biotech companies from Gyeonggi-do participated in active technical consultations and joint research discussions. Corporate needs were identified through on-site consultations and finalized after discussions with researchers. The event also included 40 consultations on beauty material distribution and three on shared patent licensing, one of which led to this successful technology transfer.
GBSA plans to continue supporting participating companies by linking customized R&D support, prototype development, and certification consulting to ensure tangible commercialization outcomes.
GBSA President Hyun-gon Kim said, “This technology transfer is a meaningful case where the R&D capabilities accumulated by GBSA over the past decade are being utilized in the industrial field,” adding, “We will continue to support Gyeonggi-based bio companies in achieving technological independence and competitiveness in the global market through the private transfer of public research outcomes.”
